Diabetic Peripheral Neuropathy Associated With Increased Health Care Costs
Researchers found a substantial cohort of adults with diabetic peripheral neuropathy in the United States with high financial and social costs.
Neuropathy
Group Acupuncture May Be Beneficial for Painful Diabetic Neuropathy
Group acupuncture may alleviate pain and improve quality of life in patients with painful diabetic neuropathy.
Treating CRPS-Associated Neuropathic Pain With EGF Receptor Inhibition
A single infusion of cetuximab was not associated with relief from therapy-resistant neuropathic pain.
Live-Attenuated Zoster Vaccine Reduces Herpes Zoster Pain and Neuralgia
Live-attenuated herpes zoster vaccine protects against postherpetic neuralgia even when [herpes zoster] occurs despite vaccination.
Neuropathic Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
For patients with chronic inflammatory demyelinating polyradiculoneuropathy, the presence of neuropathic pain leads to worsened disability and disease outcome.
Age Stratified CSF-TP Improves Diagnostic Specificity of CIDP
Updating the upper reference limits for CSF-TP according to age may aid in eliminating chances of misdiagnosing CIDP.
Noted Absence of IgM Monoclonal Gammopathy in Anti-MAG Neuropathy
The occurrence of anti-myelin-associated glycoprotein (MAG) without IgM monoclonal gammopathy is possible in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Facilitated Subcutaneous Immunoglobulin Therapy for Multifocal Motor Neuropathy
Immunoglobulin therapy facilitated by pretreatment with hyaluronidase (fSCIG) is feasible in the majority of patients with multifocal motor neuropathy (MMN) previously treated with conventional infusion of multiple small dosages (cSCIG).
Fluoroquinolone Use Linked to Increased Peripheral Neuropathy Risk
According to the results of a nested case-control study, oral fluoroquinolone exposure appears to be associated with an increased risk of incident peripheral neuropathy.
Decreased Response to Botulinum Toxin Type A Agents Observed Over Time
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
Next post in AAN 2019 Conference
